Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 40Tumor-Agnostic 28Breast 19Thoracic 5Gynecologic 4Genitourinary 4Head & Neck 3Sarcoma 2Lymphoid 2Dermatologic 2CNS 2Plasma cell 1Other 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 11Somatostatinoma 6Insulinoma 4Glucagonoma 4Gastrinoma 4Carcinoma, Neuroendocrine 4Carcinoma, Islet Cell 3Zollinger-Ellison Syndrome 2Vipoma 2Pheochromocytoma 2Pancreatic Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Adenoma, Islet Cell 2Pituitary Neoplasms 1Non functioning pancreatic endocrine tumor 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Gastro-enteropancreatic neuroendocrine tumor 1Gastro-entero-pancreatic Neuroendocrine Tumors 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Capecitabine × Endocrine × Clear all
NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Erasmus Medical Center

Phase 2 Terminated
111 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡